Pharmacodynamic Study of BKM120 in Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

BKM120 is a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, currently under investigation in a first-in-man study in patients with advanced solid tumors (wild type and PIK3CA-mutated). Consistent, dose-dependent pharmacodynamic activity has been demonstrated and clear signs of anti-tumor activity have been seen with BKM120.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

NCT01572727

Breast Cancer

COMPLETED PHASE2/PHASE3

Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer

NCT01589861

Breast Cancer

SUSPENDED PHASE1/PHASE2

BKM120 for Patients With PI3K-activated Tumors

NCT01833169

PI3K Pathway Activated Tumors

COMPLETED PHASE2

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

NCT01633060

Metastatic Breast Cancer

TERMINATED PHASE3

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer

NCT02058381

Pre-menopausal Breast Cancer PI3K Pathway Inhibition

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BKM120 is a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, currently under investigation in a first-in-man study in patients with advanced solid tumors (wild type and PIK3CA-mutated). Consistent, dose-dependent pharmacodynamic activity has been demonstrated and clear signs of anti-tumor activity have been seen with BKM120. Three breast cancer patients showed significant tumor shrinkage after ≥ 2 months. Two confirmed partial responses (PRs) per RECIST have been seen, one in a patient with a triple negative KRAS-mutated breast cancer and the other in a patient with an estrogen receptor (ER)-positive, PIK3CAmutated tumor. Two minor responses have also been observed; one of these occurred in a HER2+/ER+ breast cancer patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CBKM120

BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)during 28 days

Group Type EXPERIMENTAL

BKM120

Intervention Type DRUG

BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BKM120

BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* ER+ / HER2 negative breast cancer patients
* WHO performance status £ 2
* Previously untreated histologically confirmed invasive, non-metastatic, breast carcinoma with a tumor size ≥ 1,5cm and non urgent surgical treatment
* Activated Pi3K pathway in breast cancer trucut biopsy
* Documentation of negative pregnancy test for patients of child bearing potential within 7 days prior to start study treatment. Sexually active pre-menopausal patients must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study.
* Patients must meet the following laboratory criteria within 7 days prior to start the study treatment:
* Hematology
* Neutrophil count of \> 1200/mm3
* Platelet count of \> 100,000/ mm3
* Hemoglobin \> 90g/L
* Biochemistry
* AST/SGOT and ALT/SGPT \< 2.5 x upper limit of normal (ULN) or \< 5.0 x ULN if the transaminase elevation is due to liver metastases
* Total bilirubin \< 1.5 x ULN \[Patients with Gilbert Syndrome must have total bilirubin \< 3 ULN\]
* Cholesterol \< ULN - 7.75 mmol/L and Triglycerides \< ULN - 2.5 x ULN (with lipid-lowering drugs permitted)
* Serum creatinine \< 1.5 x ULN or 24-hour creatinine clearance \> 60 mL/min
* Serum albumin \> LLN or \> 30 g/L
* Fasting plasma glucose ≤ 140 mg/dL (7.8 mmol/L)

Exclusion Criteria

* Patients who have received prior treatment with a P13K inhibitor
* Patients with a known hypersensitivity to BKM120 or to its excipients
* Patients with a history of photosensitivity reactions to other drugs
* Patients with the following mood disorders as judged by the Investigator or a psychiatrist, or as result of patient's mood assessment questionnaire:
* Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)
* ≥ CTCAE grade 3 anxiety The psychiatric judgment overrules the mood assessment questionnaire result/investigators judgment.
* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection). Patients with unresolved diarrhea will be excluded as previously indicated
* Patients with diabetes mellitus requiring insulin treatment, history of gestational diabetes mellitus
* Impaired cardiac function or clinically significant cardiac diseases
* LVEF \< 45% as determined by MUGA scan or ECHO
* Complete left bundle branch block
* ST depression or elevation of ≥ 1.5 mm in 2 or more leads
* Congenital long QT syndrome
* History or presence of ventricular arrhythmias or atrial fibrillation
* Clinically significant resting bradycardia (\< 50 beats per minute)
* QTc \> 460 msec on screening ECG
* Right bundle branch block + left anterior hemiblock (bifascicular block)
* Unstable angina pectoris ≤ 3 months prior to starting the study drug
* Acute myocardial infarction ≤ 3 months prior to starting the study drug
* Other clinically significant heart disease such as congestive heart failure requiring treatment or uncontrolled hypertension
* Patients who have been treated with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin or darbepoetin therapy, if initiated before enrollment, may be continued
* Patients who are currently receiving treatment with medication that has the potential to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug
* Patients who are currently receiving treatment with therapeutic doses of warfarin sodium (Coumadin®)
* Patients with known coagulopathies
* Patients who have received chemotherapy, immunotherapy (except for trastuzumab) or investigational drugs ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
* Patients who have received any continuous-dosing (i.e. daily dosing, ever-other-day dosing, Monday-Wednesday-Friday dosing weekly etc) therapeutic modalities or investigational drug (excluding monoclonal antibodies) ≤ 5 half lives prior to starting study drug or who have not recovered from side effects of such therapy
* Patients who have received corticosteroids ≤ 2 weeks prior to starting study drug or who have not recovered from the side effects of corticosteroid treatment
* Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
* Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
* Women of child-bearing potential who are pregnant or breast feeding and adults of reproductive potential not employing an effective method of birth control. Adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes. Women of child-bearing potential must have a negative serum pregnancy test ≤ 7 days prior to starting BKM120
* Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatment
* Patients with a known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory)
* Patients with a history of another primary malignancy that is currently clinically significant, has potential for metastases or currently requires active intervention
* Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
* Patients with any other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol
* History of noncompliance to medical regimens
* Patients unwilling to or unable to comply with the protocol

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No